AR068901A1 - Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos - Google Patents
Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivosInfo
- Publication number
- AR068901A1 AR068901A1 ARP080104523A ARP080104523A AR068901A1 AR 068901 A1 AR068901 A1 AR 068901A1 AR P080104523 A ARP080104523 A AR P080104523A AR P080104523 A ARP080104523 A AR P080104523A AR 068901 A1 AR068901 A1 AR 068901A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- treatment
- albumin
- cognitive disorders
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente se basa en la utilizacion de albumina humana terapéutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos, en la que el modelo de administracion del medicamento comprende la administracion al paciente de un mínimo de tres veces sucesivas, de una cantidad terapéuticamente efectiva de albumina terapéutica humana mediante recambio plasmático y/o perfusion intravenosa, sin dependencia del contenido de Abeta en sangre del paciente. Reivindicacion 2: Utilizacion, segun la reivindicacion 1, caracterizada porque el medicamento adopta la forma de solucion para recambio plasmático. Reivindicacion 3: Utilizacion, segun la reivindicacion 1, caracterizada porque el medicamento adopta la forma de solucion para utilizacion intravenosa. Reivindicacion 6: Utilizacion, segun las reivindicaciones anteriores, caracterizada porque la albumina utilizada tiene una capacidad de enlace superior al de la albumina terapéutica formulada segun Farmacopea Europea.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200702831A ES2332846B1 (es) | 2007-10-26 | 2007-10-26 | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068901A1 true AR068901A1 (es) | 2009-12-16 |
Family
ID=40583637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104523A AR068901A1 (es) | 2007-10-26 | 2008-10-17 | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7851446B2 (es) |
| EP (1) | EP2111868B1 (es) |
| JP (1) | JP5437619B2 (es) |
| CN (1) | CN101417123B (es) |
| AR (1) | AR068901A1 (es) |
| AU (1) | AU2008233025B8 (es) |
| BR (1) | BRPI0804623B8 (es) |
| CA (1) | CA2641830C (es) |
| CL (1) | CL2008003133A1 (es) |
| ES (2) | ES2332846B1 (es) |
| MX (1) | MX2008013635A (es) |
| NZ (1) | NZ572131A (es) |
| PL (1) | PL2111868T3 (es) |
| PT (1) | PT2111868E (es) |
| RU (1) | RU2414925C2 (es) |
| UY (1) | UY31418A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10112000B2 (en) | 2010-07-08 | 2018-10-30 | Asahi Kasei Medical Co., Ltd. | Method for reducing amyloid beta concentration in blood |
| BR112019003172A2 (pt) * | 2016-08-18 | 2019-05-28 | Alkahest Inc | frações de plasma sanguíneo como tratamento para distúrbios cognitivos associados ao envelhecimento |
| EA039316B1 (ru) * | 2016-10-24 | 2022-01-12 | Алкахест, Инк. | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| JP7625364B2 (ja) * | 2017-04-26 | 2025-02-03 | アルカヘスト，インコーポレイテッド | 認知障害及び運動障害の血液血漿及び血液血漿製剤による治療のための投薬計画 |
| AU2019306477B2 (en) * | 2018-07-20 | 2024-08-29 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| EP3643319A1 (en) * | 2018-10-25 | 2020-04-29 | Grifols Worldwide Operations Limited | Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages |
| KR20210068573A (ko) | 2018-10-26 | 2021-06-09 | 알카헤스트 인코포레이티드 | 통증 개선, 상처 치유 및 수술 후 회복을 위한 혈장 및 혈장 분획의 용도 |
| CN116406374A (zh) * | 2020-10-30 | 2023-07-07 | 深圳普罗吉医药科技有限公司 | 人血清白蛋白在治疗疾病中的应用 |
| JP2024516390A (ja) * | 2021-04-30 | 2024-04-15 | グリフォルス・ワールドワイド・オペレーションズ・リミテッド | 認知機能障害を処置するための治療的血漿交換及び低体積血漿交換の使用 |
| WO2025230830A1 (en) | 2024-04-29 | 2025-11-06 | Alkahest, Inc. | Compositions of blood plasma fractions and their use in treatment of spinal muscular atrophy (sma) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3612137A1 (de) | 1986-04-10 | 1987-10-15 | Biotest Pharma Gmbh | Steriles plasmaaustauschmittel |
| US5112298A (en) | 1990-06-25 | 1992-05-12 | Baxter International Inc. | Apheresis method and device |
| US5178603A (en) | 1990-07-24 | 1993-01-12 | Baxter International, Inc. | Blood extraction and reinfusion flow control system and method |
| US6627151B1 (en) * | 1997-06-13 | 2003-09-30 | Helmut Borberg | Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion |
| WO2001090758A2 (en) | 2000-05-23 | 2001-11-29 | The University Of Southern California | Diagnosis of alzheimer's disease ldl receptor protein-1 |
| WO2002078670A1 (en) * | 2001-03-02 | 2002-10-10 | Neuron Therapeutics, Inc. | Neuroprotectants formulations and methods |
| WO2003051374A2 (en) | 2001-12-17 | 2003-06-26 | New York State Office Of Mental Health | SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES |
| MXPA05003607A (es) | 2002-10-04 | 2005-11-17 | Prana Biotechnology Ltd | Compuestos neurologicamente activos. |
| WO2004056318A2 (en) * | 2002-12-19 | 2004-07-08 | New York University | Method for treating amyloid disease |
| ATE362376T1 (de) | 2003-02-13 | 2007-06-15 | Octapharma Ag | Verfahren zur herstellung einer albuminlösung |
| AU2004311577A1 (en) | 2003-07-11 | 2005-07-21 | Myriad Genetics, Inc. | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease |
| AT413336B (de) * | 2003-09-12 | 2006-02-15 | Mattner Frank Dr | Apherese-vorrichtung |
| US20050182044A1 (en) | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
| AT500483B1 (de) | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
| RU2261702C1 (ru) * | 2004-09-23 | 2005-10-10 | Смирнов Алексей Владимирович | Способ лечения гипергомоцистеинемии у больных с хронической почечной недостаточностью, получающих лечение гемодиализом или гемофильтрацией |
| RU2281090C2 (ru) * | 2004-09-23 | 2006-08-10 | Алексей Владимирович Смирнов | Способ лечения больных хронической почечной недостаточностью |
| US7436304B1 (en) | 2005-07-19 | 2008-10-14 | Visible Assets, Inc | Evidence tracking |
-
2007
- 2007-10-26 ES ES200702831A patent/ES2332846B1/es not_active Expired - Fee Related
-
2008
- 2008-10-17 AR ARP080104523A patent/AR068901A1/es unknown
- 2008-10-17 NZ NZ572131A patent/NZ572131A/en unknown
- 2008-10-17 RU RU2008141076/15A patent/RU2414925C2/ru active
- 2008-10-22 PT PT83803015T patent/PT2111868E/pt unknown
- 2008-10-22 ES ES08380301T patent/ES2428698T3/es active Active
- 2008-10-22 PL PL08380301T patent/PL2111868T3/pl unknown
- 2008-10-22 EP EP08380301.5A patent/EP2111868B1/en active Active
- 2008-10-23 CN CN2008101705786A patent/CN101417123B/zh active Active
- 2008-10-23 UY UY31418A patent/UY31418A1/es not_active Application Discontinuation
- 2008-10-23 BR BRPI0804623A patent/BRPI0804623B8/pt active IP Right Grant
- 2008-10-23 CL CL2008003133A patent/CL2008003133A1/es unknown
- 2008-10-23 MX MX2008013635A patent/MX2008013635A/es active IP Right Grant
- 2008-10-24 US US12/257,814 patent/US7851446B2/en active Active
- 2008-10-24 CA CA2641830A patent/CA2641830C/en active Active
- 2008-10-24 JP JP2008274076A patent/JP5437619B2/ja active Active
- 2008-10-24 AU AU2008233025A patent/AU2008233025B8/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2641830C (en) | 2013-07-16 |
| AU2008233025A1 (en) | 2009-05-14 |
| AU2008233025B2 (en) | 2013-06-27 |
| EP2111868B1 (en) | 2013-08-21 |
| CL2008003133A1 (es) | 2009-08-07 |
| PL2111868T3 (pl) | 2014-01-31 |
| EP2111868A1 (en) | 2009-10-28 |
| JP5437619B2 (ja) | 2014-03-12 |
| BRPI0804623A2 (pt) | 2009-06-30 |
| RU2414925C2 (ru) | 2011-03-27 |
| CA2641830A1 (en) | 2009-04-26 |
| US7851446B2 (en) | 2010-12-14 |
| PT2111868E (pt) | 2013-10-17 |
| ES2332846B1 (es) | 2010-07-08 |
| NZ572131A (en) | 2010-06-25 |
| CN101417123A (zh) | 2009-04-29 |
| BRPI0804623B8 (pt) | 2021-05-25 |
| ES2428698T3 (es) | 2013-11-08 |
| CN101417123B (zh) | 2012-06-27 |
| HK1126689A1 (en) | 2009-09-11 |
| BRPI0804623B1 (pt) | 2020-02-11 |
| ES2332846A1 (es) | 2010-02-12 |
| JP2009108059A (ja) | 2009-05-21 |
| MX2008013635A (es) | 2009-05-11 |
| RU2008141076A (ru) | 2010-04-27 |
| UY31418A1 (es) | 2009-05-29 |
| AU2008233025B8 (en) | 2013-07-25 |
| US20090111740A1 (en) | 2009-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068901A1 (es) | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos | |
| Zarocostas | WHO recommends early antiviral treatment for at risk groups with suspected swine flu | |
| BRPI0820800A2 (pt) | Dispositivo médico implantável para liberação controlada de droga, e, métodos para administração de uma droga na bexiga de um paciente e para tratar a bexiga em um paciente | |
| HRP20140783T1 (hr) | Uporaba epotilona d u lijeäśenju tau-povezanih bolesti ukljuäśujuä†i alzheimerovu bolest | |
| JP2013541583A5 (es) | ||
| JP2014515408A5 (es) | ||
| WO2008067991A3 (en) | Skin-friendly drug complexes for transdermal administration | |
| JP2012524112A5 (es) | ||
| JP2010518164A5 (es) | ||
| ECSP077843A (es) | Tratamiento o prevención del prurito | |
| JP2016504361A5 (es) | ||
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| Rajput et al. | Randomized clinical trial to evaluate the efficacy of Ashtamangal Ghrita oral and Nasya in the management of cerebral palsy | |
| CN103301115B (zh) | 一种治疗癫痫的药物组合物 | |
| Cohen et al. | Mebaral in the treatment of epilepsy | |
| JP2010519274A5 (es) | ||
| Wang et al. | A new 1-sided nail brace for ingrown toenails of lesser toes | |
| CN203915760U (zh) | 一种妇科维药栓 | |
| BRPI0705630F8 (pt) | Processo de produção de vacina gênica lipossomal, vacina gênica lipossomal e uso da mesma | |
| Almomani | The effect of ketamine on blood pressure, heart rate, respiratory rate and intraocular pressure in patients undergoing ocular procedures | |
| Mahmoodiyeh et al. | Comparison between infusion pumps: Fentanyl/ketamine and fentanyl/paracetamol in pain control following tight and leg surgeries | |
| Fikri-Benbrahim et al. | Effect of pharmaceutical intervention on medication adherence and blood pressure control in treated hypertensive patients: Rationale, design and methods of the AFenPA pilot study | |
| Lintner | Metaxalone overdose | |
| JP2015512439A5 (es) | ||
| Ilchenko et al. | Prospects of aliskiren usage in diabetic patients type 2 as antihypertensive therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |